June 9, 2016 / 11:08 AM / a year ago

BRIEF-Incyte says Baricitinib significantly reduces joint damage progression in rheumatoid arthritis

June 9 (Reuters) - Incyte Corp

* Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional dmards

* Findings demonstrate baricitinib superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis Source text for Eikon: Further company coverage: )

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below